United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)

  • ID: 4384118
  • Report
  • Region: United States
  • 146 Pages
  • Renub Research
1 of 4
By 2024, the United States Molecular Diagnostics Market is Expected to Cross US$ 9 Billion

FEATURED COMPANIES

  • Abbott Laboratories
  • Becton Dickinson
  • BioMerieux
  • Cepheid
  • Myriad Genetics
  • Others...
  • MORE

United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, and Prostate) Infectious Diseases Test (Virology, HPV, HAI, and Critical Care) Genetic Test (Blood Screening, Food Pathogen, and Tissue Typing HLA)

By 2024, the United States molecular diagnostics market is expected to cross US$ 9 billion. Main factors pouring the growth of molecular diagnostics market are increased incidence of infectious diseases and different types of cancer. On the other hand, advancement of new technologies in the field of medicine and research fuels the molecular diagnostics market.

A diagnosis based on symptoms and use of substitute markers is replaced by the genomic and the proteomic analysis. Molecular diagnostics system is one of the promising systems which can transform disease diagnosis. It offers the assurance for early disease detection, potentially before symptoms have even occurred.

Molecular oncology tests have emerged as a substantial market segment. Today in the field of medical diagnostics, molecular diagnostics for cancer testing offers one of the key areas for innovation and expansion. The United States leads the regional market for blood screening and blood products. Molecular diagnostics is also a significant tool for Food Pathogen Detection Testing and HLA Testing as well as other diseases.

United State Molecular Diagnostics Market Analysis

United States molecular diagnostics market has been classified into three main categories: Oncology Test, Infectious Disease Test and Genetic Disease Test. Oncology Test has been classified into four main categories: Breast Cancer Test, Colorectal Cancer Test, Prostate Cancer Test and Other Cancer Test. Infectious Disease Test has been classified into four main categories, namely, Virology, HAI, HPV and Critical Care Test and Genetic Test has been segmented into Blood Screening, HLA and Food Pathogen Test.

United State Molecular Diagnostics Market Shares: Overview

According to this report, In the United States Molecular Diagnostics Market, Infectious Test market and the Oncology Test both have a significant market. In Molecular Oncology Test market; Breast cancer is dominating the market while in Molecular Infectious test market; Virology leads all other segments. In the area of Tests Volume; Genetics test drives all way ahead from Infectious and Oncology Test owing to Food Pathogen Test Volume.

Key Players in the United State Molecular Diagnostics Market

This report describes the players and in-depth analysis of these players, the players who played a very vital role in the development of molecular diagnostics in the United State are Roche, Hologic, Becton Dickinson, Myraid Genetics, Qiagen, Abbott, Siemens, bioMérieux and Cepheid.

United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, and Prostate) Infectious Diseases Test (Virology, HPV, HAI, and Critical Care) Genetic Test (Blood Screening, Food Pathogen, and Tissue Typing HLA) provides a comprehensive assessment of the fast-evolving, high-growth United States Molecular Diagnostics Market. This is the 2nd edition of the report.

This 146 page report with 87 Figures and 4 Tables studies the United States Molecular Diagnostics from 4 view points:

1) Molecular Diagnostics Market and Forecast
2) Segments Market & Forecast
3) Segments Test Volume & Forecast
4) Company Molecular Diagnostics Sales & Forecast

United States Molecular Diagnostics Market & Test Volume - Application Segment Analysis (2010 - 2024):

  • Oncology Test
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others
  • Infectious Diseases
    • Virology Test
    • HPV Test
    • HAI Test
    • Critical Care Test
  • Genetic Test
    • Blood Screening
    • Food Pathogen Test
    • Tissue Typing (HLA Test)

Company Sales Analysis (2010 - 2024):

1. Roche
2. Abbott
3. Myriad Genetics
4. BioMerieux
5. Qiagen
6. Hologic Inc.
7. Becton Dickinson
8. Siemens
9. Cepheid
10. Others

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Becton Dickinson
  • BioMerieux
  • Cepheid
  • Myriad Genetics
  • Others...
  • MORE

1 Executive Summary

2 United States Molecular Diagnostics Market & Forecast

3 United States Molecular Diagnostics Test Volume & Forecast

4 United States Molecular Diagnostics Market Share (2010 - 2024)
4.1 Market Share & Forecast - (Oncology, Infectious, Genetics) Tests
4.2 Segments Market Share & Forecast - (Breast, Colorectal, Prostate, Other) Cancer, (Virology, HAI, HPV, Critical Care, HLA, Blood Screening, Food Pathogen) Test
4.3 Company Market Share - (Roche, Abbott, Myriad Genetics, BioMerieux, Qiagen, Hologic Inc., Becton Dickinson, Siemens, Cepheid, Others)

5 United States Molecular Diagnostics Test Volume Share (2010 - 2024)
5.1 Volume Share & Forecast - (Oncology, Infectious, Genetics) Tests

6 Segments - United States Molecular Diagnostics Market (2010 - 2024)
6.1 Oncology Test Market Share
6.2 Oncology Test Market
6.2.1 Breast Cancer Testing Market
6.2.2 Colorectal Cancer Test Market
6.2.3 Prostate Cancer Test Market
6.2.4 Other Cancer Test Market
6.3 Market Share - Infectious Disease Test
6.4 Infectious Disease Test Market
6.4.1 Virology Test Market
6.4.2 HPV Test Market
6.4.3 HAI Test Market
6.4.4 Critical Care Test Market
6.5 Genetic Test Market Share
6.6 Genetic Test Market
6.6.1 Blood Screening Market
6.6.2 Food Pathogen Test Market
6.6.3 Tissue Typing (HLA) Test Market

7 Segments - United States Molecular Diagnostics Test Volume (2010 - 2024)
7.1 Oncology Test Volume Share
7.2 Oncology Test Volume
7.2.1 Breast Cancer Test Volume
7.2.2 Colorectal Cancer Test Volume
7.2.3 Prostate Cancer Test Volume
7.2.4 Other Cancer Test Volume
7.3 Infectious Disease Test Volume Share
7.4 Infectious Disease Test Volume
7.4.1 Virology Test Volume
7.4.2 HPV Test Volume
7.4.3 HAI Test Volume
7.4.4 Critical Care Test Volume
7.5 Genetic Test Volume Share
7.6 Genetic Testing Test Volume
7.6.1 Blood Screening Test Volume
7.6.2 Food Pathogen Test Volume
7.6.3 HLA Test Volume

8 Company - United States Molecular Diagnostics Sales & Forecast
8.1 Roche
8.2 Abbott Laboratories
8.3 Myriad Genetics
8.4 BioMerieux
8.5 Qiagen
8.6 Hologic Inc. (Acquired Gen-Probe)
8.7 Becton Dickinson
8.8 Siemens
8.9 Cepheid
8.1 Others

9 Growth Factors
9.1 Growing Automation
9.2 Rising Investment in Genomics & Proteomics Research
9.3 Personalized Medicine Fuels Molecular Diagnostics

10 Challenges
10.1 Regulatory Issues
10.2 Reimbursement Capabilities
10.3 Quality Checkpoints, Awareness & Acceptance

List of Figures
Figure 2-1: United States - Molecular Diagnostics Market (Million US$), 2010 - 2016
Figure 2-2: United States - Forecast for Molecular Diagnostics Market (Million US$), 2017 - 2024
Figure 2-3: United States - Molecular Diagnostics Test Volume (Million), 2010 - 2016
Figure 2-4: United States - Forecast for Molecular Diagnostics Test Volume (Million), 2017 - 2024
Figure 3-1: United States - Molecular Diagnostics Market Share (Percent), 2010 - 2016
Figure 3-2: United States - Forecast for Molecular Diagnostics Market Share (Percent), 2017 - 2024
Figure 3-3: United States - Molecular Diagnostics Test Volume Share (Percent), 2010 - 2016
Figure 3-4: United States - Forecast for Molecular Diagnostics Test Volume Share (Percent), 2017 - 2024
Figure 3-5: United States - Company Wise Molecular Diagnostics Market Share (Percent), 2010 - 2016
Figure 3-6: United States - Forecast for Company Wise Molecular Diagnostics Market Share (Percent), 2017 - 2024
Figure 4-1: United States - Molecular Diagnostic Oncology Testing Market (Million US$), 2010 - 2016
Figure 4-2: United States - Forecast for Molecular Diagnostic Oncology Testing Market (Million US$), 2017 - 2024
Figure 4-3: United States - Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2004 - 2016
Figure 4-4: United States - Forecast for Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2017 - 2024
Figure 4-5: United States - Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2010 - 2016
Figure 4-6: United States - Forecast for Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2017 - 2024
Figure 4-7: United States - Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2004 - 2016
Figure 4-8: United States - Forecast for Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2017 - 2024
Figure 4-9: United States - Other Molecular Diagnostic Cancer Testing Market (Million US$), 2004 - 2016
Figure 4-10: United States - Forecast for Other Molecular Diagnostic Cancer Testing Market (Million US$), 2017 - 2024
Figure 4-11: United States - Infectious Disease Testing Market (Million US$), 2010 - 2016
Figure 4-12: United States - Forecast for Infectious Disease Testing Market (Million US$), 2017 - 2024
Figure 4-13: United States - Virology Testing Market (Million US$), 2010 - 2016
Figure 4-14: United States - Forecast for Virology Testing Market (Million US$), 2017 - 2024
Figure 4-15: United States - HPV Testing Market (Million US$), 2010 - 2016
Figure 4-16: United States - Forecast for HPV Testing Market (Million US$), 2017 - 2024
Figure 4-17: United States - HAI Testing Market (Million US$), 2010 - 2016
Figure 4-18: United States - Forecast for HAI Testing Market (Million US$), 2017 - 2024
Figure 4-19: United States - Critical Care Testing Market (Million US$), 2010 - 2016
Figure 4-20: United States - Forecast for Critical Care Testing Market (Million US$), 2017 - 2024
Figure 4-21: United States - Genetic Testing Market (Million US$), 2010 - 2016
Figure 4-22: United States - Forecast for Genetic Testing Market (Million US$), 2017 - 2024
Figure 4-23: United States - Blood Screening Market (Million US$), 2006 - 2016
Figure 4-24: United States - Forecast for Blood Screening Market (Million US$), 2017 - 2024
Figure 4-25: United States - Food Pathogen Testing Market (Million US$), 2010 - 2016
Figure 4-26: United States - Forecast for Food Pathogen Testing Market (Million US$), 2017 - 2024
Figure 4-27: United States - HLA Testing Market (Million US$), 2008 - 2016
Figure 4-28: United States - Forecast for HLA Testing Market (Million US$), 2017 - 2024
Figure 5-1: United States - Oncology Test Volume (Million), 2010 - 2016
Figure 5-2: United States - Forecast for Oncology Test Volume (Million), 2017 - 2024
Figure 5-3: United States - Breast Cancer Test Volume (Million), 2004 - 2016
Figure 5-4: United States - Forecast for Breast Cancer Test Volume (Million), 2017 - 2024
Figure 5-5: United States - Colorectal Cancer Test Volume (Million), 2010 - 2016
Figure 5-6: United States - Forecast for Colorectal Cancer Test Volume (Million), 2017 - 2024
Figure 5-7: United States - Prostate Cancer Test Volume (Million), 2004 - 2016
Figure 5-8: United States - Forecast for Prostate Cancer Test Volume (Million), 2017 - 2024
Figure 5-9: United States - Other Cancer Test Volume (Million), 2004 - 2016
Figure 5-10: United States - Forecast for Other Cancer Test Volume (Million), 2017 - 2024
Figure 5-11: United States - Infectious Disease Test Volume (Million), 2010 - 2016
Figure 5-12: United States - Forecast for Infectious Disease Test Volume (Million), 2017 - 2024
Figure 5-13: United States - Virology Test Volume (Million), 2010 - 2016
Figure 5-14: United States - Forecast for Virology Test Volume (Million), 2017 - 2024
Figure 5-15: United States - HPV Test Volume (Million), 2010 - 2016
Figure 5-16: United States - Forecast for HPV Test Volume (Million), 2017 - 2024
Figure 5-17: United States - HAI Test Volume (Million), 2010 - 2016
Figure 5-18: United States - Forecast for HAI Test Volume (Million), 2017 - 2024
Figure 5-19: United States - Critical Care Test Volume (Million), 2010 - 2016
Figure 5-20: United States - Forecast for Critical Care Test Volume (Million), 2017 - 2024
Figure 5-21: United States - Genetic Testing Test Volume (Million), 2010 - 2016
Figure 5-22: United States - Forecast for Genetic Testing Test Volume (Million), 2017 - 2024
Figure 5-23: United States - Blood Screening Test Volume (Million), 2006 - 2016
Figure 5-24: United States - Forecast for Blood Screening Test Volume (Million), 2017 - 2024
Figure 5-25: United States - Food Pathogen Test Volume (Million), 2010 - 2016
Figure 5-26: United States - Forecast for Food Pathogen Test Volume (Million), 2017 - 2024
Figure 5-27: United States - HLA Test Volume (Million), 2008 - 2016
Figure 5-28: United States - Forecast for HLA Test Volume (Million), 2017 - 2024
Figure 6-1: Roche - United States Molecular Diagnostic Sales (Million US$), 2008 - 2016
Figure 6-2: Roche - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-3: Abbott Laboratories - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
Figure 6-4: Abbott Laboratories - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-5: Myriad Genetics - United States Molecular Diagnostic Sales (Million US$), 2007 - 2016
Figure 6-6: Myriad Genetics - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-7: Biomerieux - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
Figure 6-8: Biomerieux - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-9: Qiagen - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
Figure 6-10: Qiagen - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-11: Hologic-Gen-Probe - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
Figure 6-12: Hologic-Gen-Probe - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-13: Becton Dickinson - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
Figure 6-14: Becton Dickinson - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-15: Siemens - United States Molecular Diagnostic Sales (Million US$), 2008 - 2016
Figure 6-16: Siemens - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-17: Cepheid - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
Figure 6-18: Cepheid - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 6-19: Others - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
Figure 6-20: Others - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
Figure 7-1: United States - Investment in the Human Genome Project (Billion US$), 2003, 2012

List of Tables
Table 3 1: United States - Molecular Diagnostics Application Market Share (Percent), 2010 - 2016
Table 3 2: United States - Forecast for Molecular Diagnostics Application Market Share (Percent), 2017 - 2024
Table 3 3: United States - Molecular Diagnostics Application Test Volume Share (Percent), 2010 - 2016
Table 3 4: United States - Forecast for Molecular Diagnostics Application Test Volume Share (Percent), 2017 - 2024

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories
  • Becton Dickinson
  • BioMerieux
  • Cepheid
  • Hologic Inc. (Acquired Gen-Probe)
  • Myriad Genetics
  • Qiagen
  • Roche
  • Siemens
  • Others...
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll